In 2005 and 2006 the world experienced the SARS outbreak or bird flu. SARS stands for Severe Acute Respiratory Syndrome and the virus was initially spread by birds and bats.
SARS is a coronavirus similar to the present Covid-19 virus. A present search on Wikipedia states:
`The SARS related coronavirus was one of several viruses identified by the World Health Organisation in 2016 as a likely cause of a future epidemic in a new plan developed after the Ebola epidemic, for urgent research and development before and during an epidemic towards diagnostic tests, vaccines and medicines. This prediction has come to pass with the 2019-2020 coronavirus outbreak’.
The SARS-related coronavirus is an enveloped, positive sense, single stranded RNA virus that infects humans, bats, birds and other mammals.
During the last 10 days of December 2005 Fulhold Pharma Ltd conducted experiments with CHD-FA™ at the University of Tennessee, Knoxville, USA to determine whether CHD-FA™ is able to neutralize Influenza strains X31, Pr8 (a recombinant Vietnamese strain containing the NS gene from H5N1), and the bird flu strain H5N1. Testing was done using both hem agglutination assays and plaque assays.
The conclusion of the test report states: `CHD-FA™ inactivates all strains of influenza virus tested. The results from this report, coupled with existing data relating to the antiviral activity of CHD-FA™ against many strains of HIV, Vaccinia and the SARS virus, further demonstrate the broad spectrum anti-viral nature of CHD-FA™’.
These results were presented at the First Annual Conference – Avian influenza in Humans, latest advances on prevention, therapies and protective measures, 29-20 June 2006, Paris, France.